Working Groups

Home / Working Groups

To meet its core scientific objective, C-KIN has developed Working Groups with a view to increase knowledge in a number of topics pertaining to cancer and kidney related issues and consequently provide guidance and recommendations to healthcare specialists daily confronted with these issues.

C-KIN Working Groups are currently active in the following areas:

Thrombosis, Kidney disease, and Cancer

The C-KIN’s Thrombosis, Kidney disease, and Cancer Working Group (TKC) focuses on the development of Clinical practice guidelines providing guidance for treatment of Thrombosis in cancer patients with renal insufficiency.

The C-KIN TKC is supported by a LEO Pharma grant.

For more information about the TKC, visit the TKC WG page here.

BRAF inhibitors’ renal safety

Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network, by Rimda Wanchoo, Kenar D. Jhaveri, Gilbert Deray, and Vincent Launay-Vacher

BRAF inhibitors have provided a significant improvement in the care of patients with metastatic melanoma. Although randomized clinical trials did not report renal safety as a particular issue, soon after the release of these drugs, renal toxic effects, sometimes severe, and potentially impacting patients’ outcomes have been reported in the literature.

The aim of this C-KIN Working Group is to follow-up on the literature, analyze it, and provide physicians with clinical practice advices on how to follow up patients, prevent renal toxicity if possible, and treat it.

For more information about the BRAF Working Group, visit the WG page here.

Cisplatin renal toxicity

Cisplatin, and other platinum salts, still are the cornerstone of a number of tumor treatments. Although these drugs have been available for years, renal toxicity still is an issue in clinical practice, with some recent studies reporting as high as 30% of patients presenting with acute kidney injury. Methods of prevention exist, and the prevention of dehydration is key. In this view, providing patients with optimal and appropriate prevention of chemotherapy-induced nausea and vomiting appears to be of a crucial importance.

The aim of this C-KIN Working Group is thus to review available literature, and provide physicians with clinical practice guidelines.

The C-KIN CRT is supported by a Helsinn grant.

For more information about the CRT Working Group, visit the WG page here.

Anemia in cancer patients: the role of renal anemia

Anemia is still highly frequent in cancer patients. Usually considered as chemotherapy-induced, it can however also be related to the cancer itself. In patients presenting with concomitant kidney disease, which can be present in as high in 25% of patients according to the literature, anemia can also be of a renal origin. The consequences on its management, especially the use of erythropoiesis stimulating agents, are important in terms of ESA dosage, rhythm of administration, and length and target of treatment.

This C-KIN Working Group aims at reviewing the literature, and provide physicians with advice on how to discriminate between the different etiologies of anemia, and handle it the optimal way.

Members of the Working Group

  • Gilbert Deray – France – Nephrology
  • Florian Scotté – France – Oncology
  • Vincent Launay-Vacher – France – Clinical Pharmacology
Immune checkpoint inhibitors and the Kidney

Immune checkpoint inhibitors are recognized as the most recent innovations in cancer treatment. The data in metastatic melanoma and lung cancer were positive, and lead to their development in a number of different other tumors, with numerous clinical trials being conducted. However, some recent data showed that renal toxicity, through an immunologic mechanism most probably, can be an issue in the routine care of these patients.

This C-KIN Working Group aims at providing physicians and pharmaceutical firms, with recommendations on how to screen for renal toxicity, treat it, and prevent it.

Members of the Working Group

  • Vincent Launay-Vacher – France – Clinical Pharmacology
  • Kenar D. Jhaveri – USA – Nephrology
Anemia in cancer patients: Evaluating the risk of treatment-induced anemia and classification of therapies.

The incidence of anemia in cancer patients is high, and varies depending on the type of treatment the patient received. Chemotherapy-induced anemia is well-known, but chemotherapies has never been classified according to the risk of anemia, as it has been performed for chemotherapy-induced nausea and vomiting (CINV). In addition, Phase 3 studies have also reported anemia with the use of targeted therapies.

The aim of the C-KIN Working Group is to review the available data and build a classification of the risk of treatment-induced anemia, including chemotherapy and targeted therapies.

The C-KIN Working Group is supported by a Pierre Fabre grant.

For more information about the WG, visit the page here.

#mk-accordion-5a0fd2e8445b8 .mk-accordion-pane{ background-color:#ffffff; }

If you are interested in supporting one of C-KIN Working Groups, please contact us at info@c-kin.org.